Anti-cancer agents from medicinal plants
DOI:
https://doi.org/10.3329/bjp.v1i2.486Keywords:
Anti-cancer, Cytotoxicity, Medicinal plant, Natural product, TaxolAbstract
Cancer is a major public health burden in both developed and developing countries. Plant derived agents are being used for the treatment of cancer. Several anticancer agents including taxol, vinblastine, vincristine, the camptothecin derivatives, topotecan and irinotecan, and etoposide derived from epipodophyllotoxin are in clinical use all over the world. A number of promising agents such as flavopiridol, roscovitine, combretastatin A-4, betulinic acid and silvestrol are in clinical or preclinical development.
Downloads
1434
2249
References
Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005; 78: 431-41.
Bertino JR. Irinotecan for colorectal cancer. Semin Oncol. 1997; 24: S18-S23.
Butlet MS. The role of natural product chemistry in drug discovery. J Nat Prod. 2004; 67: 2141-53.
Cichewitz RH, Kouzi SA. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev. 2004; 24: 90-114.
Cox PA. Ethnopharmacology and the search for new drugs. In: Bioactive compounds from plants. Ciba Foundation Symposium 154. Chichester, England, John Wiley and Sons, 1990, pp 40-55.
Christian MC, Pluda JM, Ho TC, Arbuck SG, Murgo AJ, Sausville EA. Promising new agents under development by division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Semin Oncol. 1997; 13: 2643-55.
Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod. 1997; 60: 52-60.
Cragg GM, Newman DJ. Plants as source of anticancer agents. J Ethnopharmacol. 2005; 100: 72-79.
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, VanBelle S, Hudson I, Verweij J, Huinink WWT. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol. 1996; 14: 3056-61.
Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ. 1985; 63: 965-81.
Hartwell JL. Plants used against cancer: A survey. Lawrence, MA. Quarterman Publications, 1982, pp 438-39.
Harvey AL. Medicines from nature: Are natural products still relevant to drug discovery. Trends Pharmacol Sci. 1999; 20: 196-98.
Hoyer DL, Kung HC, Smith BL. Deaths: Preliminary data for 2003. Natl Vital Stat Rep. 2005; 53: 1-48.
Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ, Riswan S, Santarsiero B D, Mesecar AD, Wild R, Fairchild CR, Vite GD, Rose WC, Farnsworth NR, Cordell GA, Pezzuto JM, Swanson SM, Kinghorn AD. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaila silvestris. J Org Chem. 2004; 69: 3350-58.
Itokawa H, Wang X, Lee K-H. Homoharringtonine and related compounds. In: Anti-cancer agents from natural products. Cragg GM, Kingston, DGI, Newman D, (eds). Florida, Brunner-Routledge Psychology Press, Taylor & Francis Group, 2005, pp 47-70.
Jaspars M, Lawton LA. Cyanobacteria as a novel source of pharmaceuticals. Curr Opin Drug Discovery Develop. 1998; 1: 77-84.
Kantarjian HM, OBrien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 1996; 87: 3069-81.
Kappor LD. CRC Handbook of Ayurvedic medicinal plants. Florida, CRC Press, 1990, pp 416-17.
Kelland LR. Flavopiridol, the first cyclic-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin Investig Drugs. 2000; 9: 2903-11.
Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors: From starfish oocytes to clinical trials. Accounts Chem Res. 2003; 36: 417-25.
Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res. 2001; 61: 842-50.
Mi Q, Cui B, Silva GL, Lantvit D, Reyes-Lim E, Chai H, Pezzuto JM, Kinghorn AD, Swanson SM. Pervilleine F, a new tropane alkaloid aromatic ester that reverses the multidrug-resistance phenotype. Anticancer Res. 2003; 23: 3607-16.
Nahar N, Das RN, Shoeb M, Marma MS, Aziz MA, Mosihuzzaman M. Four triterpenoids from the bark of Zizyphus rugosa and Z. oenoplia. J Bangladesh Academy Sci. 1997; 21: 151-56.
Oberlines NH, Kroll DJ. Camptothecins and taxol: Historic achievement in natural products research. J Nat Prod. 2004; 67: 129-35.
Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T. New combretastatin analogues effective against murine solid tumors: Design and structure-activity relationship. J Med Chem. 1998; 41: 705-06.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55; 74-108.
Pettit GR, Singh SB, Niven ML, Hamel E, Schmit JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod. 1987; 50: 119-20.
Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit R, Schmit JM, Hogan F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5 and A-6. J Med Chem. 1995; 38: 1666-72.
Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Das Gupta TK, Pezzuto JM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995; 1: 1046-51.
Potmeisel M, Pinedo H. Camptothecins: New anticancer agents. Florida, CRC Press, 1995, pp 149-50.
Powell RG, Weisleder D, Smith CRJr, Rohwedder WK. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970; 11: 815-18.
Rowinsky EK, Onetto N, Canetta RM, Arbuck SG, Taxol: The 1st of the texanes, an important new class of anti-tumor agents. Semin Oncol. 1992; 19: 646-62.
Samuelsson G. Drugs of natural origin: A textbook of pharmacognosy. 4th ed. Stockholm, Swedish Pharmaceutical Press, 1999.
Shoeb M. Cytotoxic compounds from the Genus Centaurea. PhD Thesis. Aberdeen, UK, The Robert Gordon University, 2005.
Shoeb M, Celik S, Jaspars, M, Kumarasamy Y, MacManus S, Nahar L, Kong TLP, Sarker SD. Isolation, structure elucidation and bioactivity of schischkiniin, a unique indole alkaloid from the seeds of Centaurea schischkinii. Tetrahedron 2005; 61: 9001-06.
Shoeb M, MacManus SM, Jaspars M, Trevidadu J, Nahar L, Thoo-Lin PK, Sarker SD. Montamine, a unique dimeric indole alkaloid, from the seeds of Centaurea montana (Asteraceae), and its in vitro cytotoxic activity against the CaCo2 colon cancer cells. Tetrahedron 2006; 62: 11172-77.
Silva GL, Cui B, Chavez D, You M, Chai HB, Rasoanaive P, Lynn SM, ONeill MJ, Lewis JA, Besterman JM, Monks A, Farnsworth NR, Cordell GA, Pezzuto JM, Kinghorn AD. Modulation of the multidrug-resistance phenotype by new tropane alkaloids aromatic esters from Erythroxylum pervillei. J Nat Prod. 2001; 64: 1514-20.
Stahelin H. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer. 1973; 9: 215-21.
Wall ME, Wani MC. Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol. 1996; 51: 239-53.
Wani MC, Taylor HL, Wall M E, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971; 93: 2325-27.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
